PM360

NOVEMBER 14, 2023

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went into effect in May. The price is available to cash-paying patients with a valid prescription. References: 1.

Retail 52

Retail Pharmaceutical manufacturing Sales Insurance 52

PM360

MAY 21, 2024

The cost of filling a prescription can keep 21% of patients from getting an Rx, and one in ten patients will modify their treatment plan because of cost, according to recent polling data from KFF. It all starts with reaching HCPs and pharmacists across POC platforms with program information at the points of prescription and dispensing.

Electronics 52

Electronics Prescription Pharmaceutical manufacturing Patients 52

Clarify Health

OCTOBER 26, 2021

Not Enrolled Given this historical backdrop, the FDA and leading biotech and pharmaceutical manufacturers have taken initiatives to ensure: representative clinical trial recruitment that reflects the broader US patient population and equitable access to therapies and vaccines.

Food and Drug Administration 52

Food and Drug Administration Recruitment Pharmaceutical manufacturing Medical 52

PM360

DECEMBER 20, 2023

At the same time, a “drug lag” persists in China for global pharmaceutical companies’ products. Furthermore, the Chinese government maintains its support for local manufacturers to bridge the gap left by innovative foreign drugs or to substitute them with more cost-effective local alternatives. billion people in 2023).

Marketing 105

Marketing Insurance Medical Manufacturing 105

Penrod

JULY 9, 2024

Google’s Policy Restrictions on Healthcare Advertising Google’s internal rules heavily restrict healthcare players like pharmaceutical manufacturers. For instance, pharmaceutical manufacturers can only promote prescription medicine ads in Canada, the US, and New Zealand – not anywhere else.

Pharmaceutical manufacturing 52

Pharmaceutical manufacturing Prescription Manufacturing Medical 52

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52